US6020336A

US6020336A - Indole and indazole compounds

Info

Publication number: US6020336A
Application number: US09/146,009
Authority: US
Inventors: Gilbert Lavielle; Olivier Muller; Christine Vayssettes-Courchay; Jean-Jacques Descombes; Tony Verbeuren
Original assignee: ADIR SARL
Current assignee: Laboratoires Servier SAS
Priority date: 1997-09-03
Filing date: 1998-09-02
Publication date: 2000-02-01
Anticipated expiration: 2018-09-02
Also published as: JPH11130773A; DK0902027T5; US6046205A; NO316271B1; CA2246485C; ATE203531T1; FR2767827A1; EP0902027B1; GR3036678T3; BR9803318A; ES2162404T3; HUP9801977A1; NO984033D0; DE69801196D1; CN1087741C; AU8306898A; HK1019738A1; CN1218052A; AU736602B2; PL328323A1

Abstract

Compound of formula (I): ##STR1## wherein: n is 0 or 1,

A represents a σ bond or alkylene or alkenylene,

X represents nitrogen or C--R₂,

R₁ represents hydrogen or alkyl, and

G₁ represents any one of the groups defined in the description and medicaments containing the same.

Description

TITLE OF THE INVENTION

The present invention relates to a new indole and indazole compounds, to a process for their preparation and to pharmaceutical compositions containing them.

DESCRIPTION OF THE PRIOR ART

Many indole compounds have been described in the literature. A number of them have been studied for their 5-HT_1D -5-_1-like agonist properties. There may be mentioned by way of example Applications WO 97/11675, WO 97/06159, WO 96/04269 and GB 2289465. Patent EP 135 781 describes indazole compounds as central analgesics having neuroleptic properties.

BACKGROUND OF THE INVENTION

Serotonin (5-HT) receptors have been subdivided into seven main families, of which the 5-HT₁ receptor family forms a heterogeneous group in which a number of receptors have not yet been properly characterised.

Sumatriptan, an anti-migraine agent, interacts with 5-HT₁ receptors which have been described as being type 5-HT_1B, 5-HT_1D or 5-HT_1-like (Sumner et al., Brit. J. Pharmacol., 105, 603, 1992, Olesen, La Recherche, 23, 160, 1992). The selectivity of sumatriptan for those 5-HT_1B, 5-HT_1D and 5-HT_1-like receptors has been proposed as the main reason for its anti-migraine activity (Macon et al., J. Med. Chem., 37, 2509, 1994), in which selective vasoconstriction of the carotid vascular bed is involved (Saxena et al. T.I.P.S., 10, 200, 1989). Such receptors, which are present in the venous system, are also found in the brain, and their activation or inhibition may be at the origin of certain disorders of the central nervous system (Clitherow et al., J. Med. Chem, 37, 2253, 1994).

The compounds of the present invention have a novel structure by virtue especially of the presence of an aminated side chain that substitutes the heterocyclic nitrogen atom and of a triazole structure that substitutes the aromatic nucleus. That structure, surprisingly, provides the compounds of the invention with a high selectivity for the 5-HT_1B, 5-HT_1D and 5-HT_1-like receptors. They are thus able to be used as a venotonic agent in the treatment of venous insufficiency and of associated disorders, and also in the treatment of migraine and conditions associated with that disorder, "cluster headaches", pain, migraine associated with vascular disorders, and in hypertension, obesity and eating disorders.

The activity of the compounds of the invention has been evaluated in a pharmacological test that measures their potential for contracting the saphenous vein isolated from a dog or rabbit, as described by Humphrey et al. (Br. J. Pharmacol., 94, 1123, 1988).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to compounds of formula (I): ##STR2## wherein: n is 0 or 1,

A represents a σ bond or a linear or branched (C₁ -C₈)alkylene group or a linear or branched (C₁ -C₈)alkenylene group,

X represents a nitrogen atom or a C--R₂ group wherein R₂ represents a hydrogen atom or a linear or branched (C₁ -C₆)alkyl group,

R₁ represents a hydrogen atom or a linear or branched (C₁ -C₆)alkyl group,

G₁ represents a pyrrolidinyl or piperidyl group, each of those groups being optionally substituted on any of the junctions of the ring by a linear or branched (C₁ -C₆)alkyl group, (C₃ -C₇)cycloalkyl group, (C₃ -C₇)cycloalkyl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, nitrile group, carboxy group, linear or branched (C₁ -C₆)alkoxycarbonyl group, carbamoyl group (optionally substituted by one or two linear or branched (C₁ -C₆)alkyl, (C₃ -C₇)cycloalkyl, optionally substituted phenyl and/or optionally substituted benzyl groups), optionally substituted aryl group, optionally substituted aryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, optionally substituted heteroaryl group or optionally substituted heteroaryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched,

it being understood that those pyrrolidine and piperidine groups may be bonded to A by any one of the atoms of the ring,

or G₁ represents a group ##STR3## wherein: R₃ and R₄ each independently of the other represent a hydrogen atom, or a linear or branched (C₁ -C₆)alkyl group, (C₃ -C₇)cycloalkyl group, (C₃ -C₇)cycloalkyl-(C₁ -C₆)-alkyl group in which the alkyl is linear or branched, optionally substituted aryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched or optionally substituted aryl group, or, together with the nitrogen atom that carries them, form a group: ##STR4## wherein B represents a σ bond or a linear or branched (C₁ -C₆)alkylene group and R₅ represents a hydrogen atom or a linear or branched (C₁ -C₆)alkyl group, (C₃ -C₇)-cycloalkyl group, optionally substituted aryl group, optionally substituted aryl-(C₁ -C₆)-alkyl group in which the alkyl is linear or branched, optionally substituted heteroaryl group or optionally substituted heteroaryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched,

their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

"Aryl group" is understood to mean a group selected from phenyl and naphthyl.

"Heteroaryl group" is understood to mean a group selected from furyl, thienyl, pyridyl, pyrrolyl, imidazolyl, tetrazolyl, pyrazinyl and pyrimidinyl.

The term optionally substituted applied to the terms "phenyl", "benzyl", "aryl", "arylalkyl", "heteroaryl" and "heteroarylalkyl" means that the groups in question are substituted by one or more halogen atoms and/or linear or branched (C₁ -C₆)alkyl, linear or branched (C₁ -C₆)alkoxy, hydroxy and/or linear or branched (C₁ -C₆)trihaloalkyl groups.

Amongst the pharmaceutically acceptable acids, there may be mentioned by way of non-limiting example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphonic acid, glutaric acid, fumaric acid, tartaric acid, maleic acid, citric acid, ascorbic acid, methanesulphonic acid, camphoric acid, oxalic acid, etc.

Amongst the pharmaceutically acceptable bases, there may be mentioned by way of non-limiting example sodium hydroxide, potassium hydroxide, triethylamine, tert-butylamine, etc.

Advantageously, the present invention relates to compounds of formula (I) wherein the triazolyl or triazolylmethyl group is attached to the 6-position of the indole or indazol group.

A further advantageous aspect of the invention relates to compounds of formula (I) wherein the triazolyl or triazolylmethyl group is attached to the 5-position of the indole or indazole group.

The preferred compounds of the invention are those wherein n is 0.

The invention relates preferably to compounds of formula (I) wherein X represents a CR₂ group, R₂ preferably being a hydrogen atom.

Other preferred compounds of formula (I) are those wherein X represents a nitrogen atom.

In the compounds of formula (I), R₁ preferably represents a hydrogen atom.

Preferably the invention relates to compounds of formula (I) wherein, in the substituent A--G₁, A represents a σ bond or a linear or branched (C₁ -C₆)alkylene group, and G₁ represents a pyrrolidinyl (for example 3-pyrrolidinyl), piperidyl (for example 4-piperidyl) or 1-piperazinyl group, those groups being substituted or unsubstituted. Amongst the preferred substituents, there may be mentioned advantageously the following groups: linear or branched (C₁ -C₆)alkyl, aryl, aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, heteroaryl and/or heteroaryl-(C₁ -C₆)-alkyl in which the alkyl is linear or branched. The pyrrolidinyl and piperidyl groups are advantageously substituted on the nitrogen atom.

A further preferred aspect of the invention relates to compounds of formula (I) wherein A represents a linear or branched (C₁ -C₆)alkylene group and G₁ represents a group ##STR5## wherein R₃ and R₄ each independently of the other represent a hydrogen atom, or a linear or branched (C₁ -C₆)alkyl group, (C₃ -C₇)-cycloalkyl group, (C₃ -C₇)cycloalkyl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, optionally substituted aryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched or optionally substituted aryl group. Advantageously R₃ and R₄ represent a linear or branched (C₁ -C₆)alkyl group.

More especially, the invention relates to compounds of formula (I) wherein the triazolyl or triazolylmethyl group is attached to the 6-position of the indole or indazole group, X represents a --CH-group or a nitrogen atom, R₁ represents a hydrogen atom, A represents a σ bond or a linear or branched (C₁ -C₆)alkylene group, whilst G₁ represents a pyrrolidinyl or piperidinyl group optionally substituted on any of the junctions of the ring by a linear or branched (C₁ -C₆)alkyl group, optionally substituted aryl group, optionally substituted aryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, optionally substituted heteroaryl group or optionally substituted heteroaryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, or G₁ represents a 1-piperazinyl group optionally substituted on the nitrogen atom in the 4-position by a linear or branched (C₁ -C₆)alkyl group, optionally substituted aryl group, optionally substituted aryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, optionally substituted heteroaryl group or optionally substituted heteroaryl-(C₁ -C₆)alkyl group in which the alkyl is linear or branched, or A represents a linear or branched (C₁ -C₆)alkylene group whilst G₁ represents a group ##STR6## wherein R₃ and R₄ each independently of the other represent a hydrogen atom or a linear or branched (C₁ -C₆)alkyl group.

The invention relates also to a process for the preparation of the compounds of formula (I), characterised in that,

when, in the desired compound of formula (I), X represents a C--R₂ group, there is used as starting material a compound of formula (II/a): ##STR7## wherein R₁ and R₂ are as defined for formula (I), and Y represents a nitro group if, in the desired compound of formula (I), n is 0, or Y represents a hydroxymethyl group if, in the desired compound of formula (I), n is 1,

which is condensed.

either with a compound of formula (III/a):

Z--A--G.sub.1                                              (III/a)

wherein A and G₁ are as defined for formula (I) and Z represents a halogen atom or a formyl group,

to yield a compound of formula (IV): ##STR8## wherein A, Y, G₁, R₁ and R₂ are as defined hereinabove, which is subjected to an oxidation reaction to yield a compound of formula (V/a): ##STR9## wherein A, Y, G₁, R₁ and R₂ are as defined hereinabove, and the G₁ group, when it represents a pyrrolidinyl, piperidinyl or piperazinyl group, is, if desired, substituted on the nitrogen atom in a basic medium or by a reductive amination reaction with a carbonyl compound,

or with a compound of formula (III/b), in a basic medium:

Br--A--OH                                                  (III/b)

wherein A is as defined hereinabove,

to yield a compound of formula (IV'): ##STR10## wherein Y, A, R₁ and R₂ are as defined hereinabove, which, after bromination and oxidation, is condensed with a compound of formula G₁ H, G₁ being as defined for formula (I), to yield a compound of formula (V/a), as defined hereinabove,

or,

when, in the desired compound of formula (I), X represents a nitrogen atom, there is used as starting material a compound of formula (II/b): ##STR11## wherein Y and R₁ are as defined hereinabove, which is condensed

either with a compound of formula (III/c), in a basic medium:

Hal--A--G.sub.1                                            (III/c)

wherein A and G₁ are as defined hereinabove, and Hal represents a halogen atom, to yield a compound of formula (V/b): ##STR12## wherein A, Y, G₂ and R₁ are as defined hereinabove, and the G₁ group, when it represents a pyrrolidinyl, piperidyl and piperazinyl group, is, if desired, substituted on the nitrogen atom in a basic medium or by a reductive amination reaction with a carbonyl compound,

or with a compound of formula (III/b) as defined hereinabove, to yield a compound of formula (VI): ##STR13## wherein Y, A and R₁ are as defined hereinabove, which, after bromination, is condensed with a compound of formula HG₁, G₁ being as defined for formula (I), to yield a compound a formula (V/b) as defined hereinabove,

which compounds of formulae (V/a) and (V/b) constitute the totality of the compounds of formula (V): ##STR14## wherein X, Y, A, R₁ and G₁ are as defined for formula (I), and Y is as defined hereinabove,

which, by reduction of the Y group (when Y represents a hydroxymethyl group, after conversion to an azido compound), yields a compound of formula (VII): ##STR15## wherein n, X, A, G₁ and R₁ are as defined hereinabove, which is condensed with N,N-dimethylformamide azine, in an acidic medium, to yield the compounds of formula (I),

which are optionally purified in accordance with a conventional purification technique,

optionally separated into their enantiomers in accordance with a conventional separation technique, and

converted, where appropriate, into addition salts thereof with a pharmaceutically acceptable acid or base,

it being understood that when Y contains a hydroxy group, it can be protected or deprotected depending on the reagents used.

The invention relates also to pharmaceutical compositions that comprise as active ingredient at least one compound of formula (I) on its own or in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients of carriers. Amongst the pharmaceutical compositions according to the invention, there may be mentioned more especially those that are suitable for oral, parenteral or nasal administration, tablets or dragees, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, dermal gels, etc.

The useful dosage varies according to the age and weight of the patient, the nature and severity of the disorder, and the route of administration, which may be nasal, rectal, parenteral or oral. The unit does generally ranges from 1 to 500 mg for treatment in from 1 to 3 administrations per 24 hours.

The following Examples illustrate the invention and do not limit it in any way. The structures of the compounds described have been confirmed by the customary spectroscopic techniques.

EXAMPLE 1 1-(N-tert-butyloxycarbonyl-pyrrolidin-3-ylmethyl)-6-([1,2,4]triazol-4-yl)indole

Step a: 1-(N-tert-butyloxycarbonyl-pyrrolidin-3-ylmethyl)-6-nitro-2,3-dihydroindole

91.5 mmol (19.4 g) of solid sodium triacetoxyborohydride are added slowly, at 20° C., to a solution of 60.8 mmol (12.1 g) of 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine, 60.8 mmol (10 g) of 6-nitroindoline and 60.8 mmol (3.65 g) of acetic acid in 100 ml of dichloromethane. After 2 hours' stirring, the reaction mixture is diluted with ethyl acetate. The organic phase is washed with water until pH=8, and the aqueous phase is then extracted with dichloromethane. After removal of the solvent by evaporation, the expected product is obtained.

Step b: 1-(N-tert-butyloxycarbonyl-pyrrolidin-3-ylmethyl)-6-nitroindole

100 g of maganese dioxide are added to a solution of 63.4 mmol (20 g) of the compound obtained in the preceding Step in 1 liter of toluene. The reaction mixture is heated at reflux for 2 hours. After cooling, the mineral salts are filtered off and the filtrate is concentrated. The residue is purified by chromatography on silica gel using a dichloromethane/methanol mixture (99/1) as eluant to obtain the expected product.

Step c: 6-Amino-1-(N-tert-butyloxycarbonyl-pyrrolidin-3-ylmethyl)indole

A solution of 28.1 mmol (9.7 g) of the compound described in the preceding Step in 350 ml of ethanol is stirred for 15 minutes in the presence of 4.7 g of palladium-on-carbon under hydrogen atmospheric pressure. The catalyst is removed by filtration, and the filtrate is concentrated to yield the expected compound.

Step d: 1-(N-tert-butyloxycarbonyl-pyrrolidin-3-ylmethyl)-6-([1,2,4]triazol-4-yl)indole

A solution of 24.8 mmol of the compound described in the preceding Step, 24.6 mmol of N,N-dimethylformamide azine (obtained in accordance with the process described in J. Med. Chem., 1967, 1664) and 300 mg of para-toluenesulphonic acid in 100 ml of toluene is refluxed for 12 hours. After cooling, the organic phase is washed with water, and the aqueous phase is extracted with dichloromethane. The different organic phases are combined and concentrated, and the residue is purified by chromatography on silica gel using a dichloromethane/methanol/ammonia mixture (95/5/0.5) as eluant to yield the expected compound.

EXAMPLE 2 1-(Dimethylaminoethyl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, step d, starting with 6-amino-1-(2-dimethylaminoethyl)indole described in Application WO 95/32967. The corresponding dihydrochloride is obtained by the action of a titrated solution of hydrochloric acid in ethanol.

Melting point: 254-256° C.

EXAMPLE 3 1-(1-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-(1-Benzylpiperid-4-yl)-6-nitro-2,3-dihydroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-benzyl-4-piperiodone.

Step b: 1-(1-Benzylpiperid-4-yl)-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step b, starting from the compound described in the preceding Step.

Step c: 6-Amino-1-(1-benzylpiperid-4-yl)indole

The expected product is obtained in accordance with the process in Example 1, Step c, starting from the compound described in the preceding Step.

Step d: 1-(1-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indole, dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Step d, starting from the compound described in the preceding Step, followed by treatment of the base with a titrated solution of hydrochloric acid in ethanol.

EXAMPLE 4 1-[3-(4-Benzylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-(3-Hydroxypropyl)-6-nitroindole

0.13 mol of potassium tert-butylate and 0.13 mol of 3-bromopropanol are added to a solution of 0.11 mol of 6-nitroindole in 400 ml of dimethylformamide. The reaction mixture is heated at 80° C. for 3 hours. After cooling, 300 ml of a 10% potassium carbonate solution are added, and the mixture is diluted with ethyl acetate. After decanting, the aqueous phase is extracted with dichloromethane, and the combined organic phases are then concentrated and purified by chromatography on silica gel to yield the expected product.

Step b: 1-(3-Bromopropyl)-6-nitroindole

0.12 mol of carbon tetrabromide, and then a solution of 0.12 mol of triphenylphosphine dissolved in 100 ml of dichloromethane, are added to a solution of 0.1 mol of the compound described in the preceding Step in 300 ml of dichloromethane. After 4 hours' stirring at room temperature, the reaction mixture is concentrated and purified by chromatography on silica gel to yield the expected compound.

Step c: 1-[3-(4-Benzylpiperid-1-yl)-propyl]-6-nitroindole

12 mmol of triethylamine and 12 mmol of 4-benzylpiperidine are added to a solution of 10 mmol of the compound described in the preceding Step in 30 ml of diethyl ketone. The reaction mixture is stirred for 6 hours at room temperature. After hydrolysis, the mixture is diluted with ethyl acetate and extracted. The organic phases are concentrated and purified by chromatography on silica gel to yield the expected compound.

Step d: 6-Amino-1-[3-(4-benzylpiperid-1-yl)propyl]-indole

The expected product is obtained in accordance with the process described in Example 1, Step c, starting from the compound described in the preceding Step.

Step e: 1-[3-(4-Benzylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Step d, starting from the compound described in the preceding Step. The corresponding dihydrochloride is obtained by the action of a titrated solution of hydrochloric acid in ethanol.

EXAMPLE 5 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]-triazol-4-yl)indole dihydrochloride

Step a: 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-nitroindole

The expected product is obtained in accordance with the process described in Example 4, Step c, replacing 4-benzylpiperidine by 4-(5-methoxypyrimidin-4-yl)piperazine.

Step b: 6-Amino-1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-indole

Step c: 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]-triazol-4-yl)indole, dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Step d, starting from the compound described in the preceding Step. The corresponding hydrochloride is obtained by the action of a titrated solution of hydrochloric acid in ethanol.

Melting point: 130-132° C.

EXAMPLE 6 1-(Dimethylaminoethyl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

Step a: 1-(2-Dimethylaminoethyl)-6-nitroindazole

0.11 mol of potassium tert-butylate is added to a solution of 0.11 mol (20 g) of 6-nitroindazole in 400 ml of tetrahydrofuran. After total dissolution, a solution of 0.24 mol (27 g) of 2-chlorothyl-N,N-dimethylamine in 300 ml of toluene is added. The reaction medium is heated at reflux for 3 hours. After cooling, 300 ml of a 10% sodium carbonate solution are added. The mixture is diluted with ethyl acetate and decanted, and the aqueous phase is extracted with dichloromethane. After concentration of the organic phases, the residue is purified by chromatography on silica gel using a dichloromethane/methanol mixture (98/2) as eluant to yield the expected compound.

Step b: 6-Amino-1-(2-dimethylaminoethyl)indazole

Step c: 1-(2-Dimethylaminoethyl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

EXAMPLE 7 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]-triazol-4-yl)indazole

Step a: 1-(3-Hydroxypropyl)-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 4, Step a, replacing 6-nitroindole by 6-nitroindazole, and after separating the resulting positional isomers.

Step b: 1-(3-Bromopropyl)-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 4, Step b, starting from the compound described in the preceding Step.

Step c: 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 4, Step c, starting from the compound described in the preceding Step, replacing 4-benzylpiperidine by 4-(5-methoxypyrimidin-4-yl)piperazine.

Step d: 6-Amino-1-{3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-indazole

Step e: 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]-triazol-4-yl)indazole

The expected product is obtained in accordance with the process described in Example 1, Step d, starting from the compound described in the preceding Step.

EXAMPLE 8 1-(1-Methylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: (1-Methylpiperid-4-yl)-6-nitro-2,3-dihydroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-methyl-4-piperidone.

Step b: 1-(1-Methylpiperid-4-yl)-6-nitroindole

Step c: 6-Amino-1-(1-methylpiperid-4-yl)indole

Step d: 1-(1-Methylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The resulting base is then converted into a salt with a titrated solution of hydrochloric acid in ethanol.

Melting point: 195-198° C.

EXAMPLE 9 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-nitroindole

The expected product is obtained in accordance with the process described in Example 4, Step c, replacing 4-benzylpiperidine by N-(2-phenylethyl)piperazine.

Step b: 6-Amino-1-{3-[4-(2-phenylethyl)piperazin-1-yl]propyl}indole

Step c: 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)-indole dihydrochloride

Melting point: >270° C.

EXAMPLE 10 1-(Pyrrolidin-3-ylmethyl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

A solution of 30 mmol of the compound described in Example 1 in 300 ml of ethyl acetate is treated for 4 minutes at -10° C. with a stream of hydrochloric acid. The resulting precipitate is filtered off and rinsed with ether to yield the title product.

Melting point: 206° C.

EXAMPLE 11 1-[(N-Ethylpyrrolidin-3-yl)methyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-(Pyrrolidin-3-ylmethyl)-6-nitroindole

The expected product is obtained in accordance with the process described in Example 10, using the compound described in Example 1, Step b, as starting material.

Step b: 1-[(N-Ethylpyrrolidin-3-yl)methyl]-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by acetaldehyde, and using the compound described in the preceding Step as starting material.

Step c: 1-[(N-Ethylpyrrolidin-3-yl)methyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Steps c and d, using the compound described in the preceding Step as starting material. The corresponding dihydrochloride is obtained by the action of a titrated solution of hydrochloric acid in ethanol.

EXAMPLE 12 1-{[N-Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl) indole dihydrochloride

Step a: 1-{[N-Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by cyclohexanecarboxaldehyde, and using the compound described in Step a of Example 11 as starting material.

Step b: 1-{[N-Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 13 1-{[N-(2-Furylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl) indole dihydrochloride

Step a: 1-{[N-(2-Furylmethyl)pyrrolidin-3-yl]methyl}-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-furfuraldehyde, and using the compound described in Step a of Example 11 as starting material.

Step b: 1-{[N-(2-Furylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 14 1-{[N-(2-Pyridylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl) indole dihydrochloride

Step a: 6-Nitro-1-{[N-(2-pyridylmethyl)pyrrolidin-3-yl]methyl}indole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-pyridinecarboxaldehyde, and using the compound described in Step a of Example 11 as starting material.

Step b: 1-{[N-(2-Pyridylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 15 1-(4-Piperidyl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 6-Nitro-1-(1-carbethoxy-4-piperidyl)indole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-carbethoxy-4-piperidone.

Step b: 1-(1-Carbethoxy-4-piperidyl)6-([1,2,4]triazol-4-yl)indole

The expected product is obtained in accordance with the process described in Example 1, Steps c and d, using the compound described in the preceding Step as starting material.

Step c: 1-(4-Piperidyl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 10, using the compound described in the preceding Step as starting material and an aqueous solution of chlorhydric acid.

EXAMPLE 16 1-[1-(2-Pyridylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 6-Nitro-1-[1-(2-pyridylmethyl)piperid-4-yl]indole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-pyridinecarboxaldehyde, and using the compound described in Example 15, step a, as starting material.

Step b: 1-[1-(2-Pyridylmethyl)piperid-4-yl]6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 17 1-[1-(2-(2-Furylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-[1-(2-(2-Furylmethyl)piperid-4-yl]-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-furfuraldehyde, and using the compound described in Example 15, step a, as starting material.

Step b: 1-[1-(2-(2-Furylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 18 1-[1-(3-Phenylpropyl)piperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 6-Nitro-1-[1-(3-phenyl-2-propenyl)piperid-4-yl)indole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by cinnamic aldehyde, and using the compound described in Example 15, step a, as starting material.

Step b: 1-[1-(3-Phenylpropyl)piperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 19 1-[1-(Cyclohexylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

Step a: 1-[1-(Cyclohexylmethyl)piperid-4-yl]-6-nitroindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by cyclohexanecarboxaldehyde, using the compound described in Example 15, step a, as starting material.

Step b: 1-[1-(Cyclohexylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

EXAMPLE 20 1-[3-(2-Methylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 2-methylpiperidine in Step c.

EXAMPLE 21 1-[3-(4-Methylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 4-methylpiperidine in Step c.

EXAMPLE 22 1-[3-(2,6-Dimethylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 2,6-dimethylpiperidine in Step c.

EXAMPLE 23 1-[3-(3,5-Dimethylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl)-indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 3,5-dimethylpiperidine in Step c.

EXAMPLE 24 1-[2-(Benzylamino)ethyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 3-bromopropanol by 2-bromoethanol in Step a and replacing 4-benzylpiperidine by benzylamine in Step c.

EXAMPLE 25 1-[3-(Benzylamino)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by benzylamine in Step c.

EXAMPLE 26 1-[3-(Phenylamino)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by aniline in Step c.

EXAMPLE 27 1-[3-(Cyclohexylamino)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by cyclohexylamine in Step c.

EXAMPLE 28 1-[3-(1-Piperazinyl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by piperazine in large excess in Step c.

EXAMPLE 29 1-[3-(4-Phenylpiperazin-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 4-phenylpiperazine in Step c.

EXAMPLE 30 1-{3-[4-(2-Pyridyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)-indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 1-(2-pyridyl)piperazine in Step c.

EXAMPLE 31 1-[3-(4-Methylpiperazin-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 1-methylpiperazine in Step c.

EXAMPLE 32 1-[3-(4-Cyclohexylpiperazin-1-yl)propyl]-6-([1,2,4]triazol-4-yl)-indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by cyclohexylpiperazine in Step c.

EXAMPLE 33 1-{3-[4-(2-Pyridylmethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride Step a: 6-Nitro-1-{3-[4-(2-pyridylmethyl)piperazin-1-yl]propyl}indole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-pyridinecarboxaldehyde, and using 6-nitro-1-[(1-piperazinyl)propyl]indole (isolated in the course of the process for the preparation of the compound described in Example 28) as starting material.

Step b: 1-{3-[4-(2-Pyridylmethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4yl)indole dihydrochloride

EXAMPLE 34 1-{3-[4-(3-Trifluoromethylphenyl)piperazin-1-yl)propyl}-6-([1,2,4]-triazol-4-yl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, replacing 4-benzylpiperidine by 1-(3-trifluoromethylphenyl)piperazine in Step c.

EXAMPLE 35 1-[N-(tert-butyloxycarbonylpyrrolidin-3-yl)methyl]-6-([1,2,4]-triazol-4-yl)indazole

The expected product is obtained in accordance with the process described in Example 1, Steps a, c and d, replacing 6-nitroindoline by 6-nitroindazole.

EXAMPLE 36 1-(3-Pyrrolidinylmethyl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 10, using the compound described in Example 35 as starting material.

EXAMPLE 37 1-{[N-(Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 6-Nitro-1-(3-pyrrolidinylmethyl)indazole

The expected product is obtained in accordance with the process described in Example 10, using as starting material 1-[N-(tert-butyloxycarbonylpyrrolidin-3-yl)methyl]-6-nitroindazole, isolated in the course of the process for the preparation of the compound described in Example 35.

Step b: 1-{[N-(Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by cyclohexanecarboxaldehyde, and using the compound described in the preceding Step as starting material.

Step c: 1-{[N-(Cyclohexylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)-indazole dihydrochloride

The corresponding dihydrochloride is obtained by the action of a titrated solution of hydrochloric acid in ethanol.

EXAMPLE 38 1-{[N-(2-Pyridylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 6-Nitro-1-{[N-(2-pyridylmethyl)pyrrolidin-3-yl]methyl}indazole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-pyridinecarboxaldehyde, and using the compound described in Example 37, Step a, as starting material.

Step b: 1-{[N-(2-Pyridylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-yl)indazole, dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Steps c and d, using the compound described in preceding Step as starting material. The corresponding dihydrochloride is obtained by the action of a titrated solution of hydrochloric acid ethanol.

EXAMPLE 39 1-(4-Piperidyl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 6-Nitro-1-(1-carbethoxy-4-piperidyl)indazole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-carbethoxy-4-piperidone, and using 6-nitroindazole as starting material.

Step b: 1-(1-Carbethoxy-4-piperidyl)-6-([1,2,4]triazol-4-yl)indazole

Step c: 1-(4-Piperidyl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

EXAMPLE 40 1-(N-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 1-(N-Benzylpiperid-4-yl)-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-benzyl-4-piperidone, and using 6-nitroindazole as starting material.

Step b: 1-(N-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

EXAMPLE 41 1-[N-(2-Furylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 1-[N-(2-Furylmethyl)piperid-4-yl]-6-nitroindazole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by 2-furfuraldehyde, and using the compound described in Example 39, Step a, as starting material.

Step b: 1-[N-(2-Furylmethyl)piperid-4-yl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

EXAMPLE 42 1-(N-Methylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride Step a: 1-(N-Methylpiperid-4-yl)-6-nitroindazole

Step b: 1-(N-Methylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

EXAMPLE 43 1-[3-(Benzylamino)propyl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by benzylamine in Step c, and using hydrazine in the presence of nickel as reductive agent, in step d.

EXAMPLE 44 1-[3-(1-Piperazinyl)propyl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by piperazine in large excess in Step c.

EXAMPLE 45 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by 4-(2-phenylethyl)piperazine in Step c.

EXAMPLE 46 1-{3-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]propyl}-6-([1,2,4]-triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by 1-(3-trifluoromethylphenyl)piperazine in Step c.

EXAMPLE 47 1-[3-(4-Methylpiperazin-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by 1-methylpiperazine in Step c.

EXAMPLE 48 1-[3-(4-Cyclohexylpiperazin-1-yl)propyl]-6-([1,2,4]triazol-4-yl)indazole dihydrochloride

The expected product is obtained in accordance with the process described in Example 4, using 6-nitroindazole as starting material, and replacing 4-benzylpiperidine by cyclohexylpiperazine in Step c.

The compounds of Examples 49 to 56 are obtained in accordance with the process described in the preceding Examples, using 3-methyl-6-nitroindole as starting material.

EXAMPLE 49 1-(Dimethylaminoethyl)-3-methyl-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 50 3-Methyl-1-[(pyrrolidin-3-yl)methyl]-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 51 3-Methyl-1-(1-methylpiperid-4-yl)-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 52 1-(1-Benzylpiperid-4-yl)-3-methyl-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 53 1-[3-(4-Benzylpiperid-1-yl)propyl]-3-methyl-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 54 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-3-methyl-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 55 3-Methyl-1-{3-[4-(2-phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 56 1-[3-(4-Methylpiperazine-1-yl)propyl]-3-methyl-6-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 57 1-(1-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride Step a: 1-(1-Benzylpiperid-4-yl)-6-hydroxymethylindole

The expected product is obtained in accordance with the process described in Example 1, Step a, replacing 1-(tert-butyloxycarbonyl)-3-formylpyrrolidine by N-benzylpiperidone and using 6-hydroxymethylindole (prepared from the corresponding carboxylic acid) as starting material.

Step b: [1-(1-Benzylpiperid-4-yl)-6-indolyl]methyl methanesulfonate

14.5 mmol (2 ml) of triethylamine and, dropwise, 14.5 mmol (1.12 ml) of mesylchloride are added to a solution of 12 mmol (3.85 g) of the compound described in the preceding Step in 50 ml of dichloromethane.

The reaction mixture is stirred for 5 hours at room temperature. After hydrolysis and extraction with dichloromethane, the organic phase is washed by a 0.1 N aqueous hydrochloric acid solution, dried and concentrate to yield the expected compound.

Step c: 6-(Azidomethyl)-1-(1-benzylpiperid-4-yl)indole

21.6 mmol of sodium azide are added to a solution of 10.8 mmol of the compound described in the preceding Step in 20 ml of dimethylsulfoxyde. The reaction mixture is stirred for 1 hour at room temperature. After hydrolysis, the reaction medium is extracted with ethylacetate, and the organic phase is dried and concentrate to yield the expected product.

Step d: 6-Aminomethyl-1-(1-benzylpiperid-4-yl)indole

The expected product is obtained in accordance with the process described in Example 1, Step c, using the compound described in the preceding Step as starting material.

Step e: 1-(1-Benzylpiperid-4-yl)-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride

The expected product is obtained in accordance with the process described in Example 1, Step d, using the compound described in the preceding Step as starting material.

Melting point: >270° C. (dec.)

In the same manner compounds of example 58 to 65 are obtained.

EXAMPLE 58 1-(1-Methylpiperid-4-yl)-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride EXAMPLE 59 1-[3-(4-benzylpiperid-1-yl)propyl]-6-([1,2,4]triazol-4-yl-methyl)indole dihydrochloride EXAMPLE 60 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride EXAMPLE 61 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride EXAMPLE 62 1-{[N-(2-Pyridylmethyl)pyrrolidin-3-yl]methyl}-6-([1,2,4]triazol-4-ylmethyl)indole dihydrochloride EXAMPLE 63 1-(Dimethylaminoethyl)-6-([1,2,4]triazol-4-ylmethyl)indazole dihydrochloride EXAMPLE 64 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-ylmethyl)indazole dihydrochloride EXAMPLE 65 1-{3-[4-(5-Methoxypyrimid-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-ylmethyl)indazole dihydrochloride

The compounds of Examples 66 to 79 are obtained using processes similar to those described in the preceding Examples, replacing the 6-nitroindole and 6-nitroindazole starting materials by 5-nitroindole and 5-nitroindazole.

EXAMPLE 66 1-(Dimethylaminoethyl)-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 67 1-(Pyrrolidin-3-ylmethyl)-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 68 1-(1-Methylpiperid-4-yl)-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 69 1-[1-(2-Pyridylmethyl)piperid-4-yl]-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 70 1-(1-Benzylpiperid-4-yl)-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 71 1-[3-(4-Benzylpiperid-1-yl)propyl]-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 72 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 73 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 74 1-{3-[4-(3-Trifluoromethylphenyl)piperazin-1-yl]propyl}-5-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 75 1-(Dimethylaminoethyl)-5-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 76 1-(1-Methylpiperid-4-yl)-5-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 77 1-[3-(4-Benzylpiperid-1-yl)propyl]-5-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 78 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-5-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 79 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-5-([1,2,4]triazol-4-yl)indazole dihydrochloride

The compounds of Examples 80 to 85 are obtained in the same manner, using 4-nitroindole as starting material.

EXAMPLE 80 1-(Dimethylaminoethyl)-4-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 81 1-(Pyrrolidin-3-ylmethyl)-4-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 82 1-(1-Methylpiperid-4-yl)-4-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 83 1-[3-(4-Benzylpiperid-1-yl)propyl]-4-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 84 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-4-([1,2,4]triazol-4-yl)indole dihydrochloride EXAMPLE 85 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-4-([1,2,4]triazol-4-yl)indole dihydrochloride

The compounds of Examples 86 to 90 are obtained in the same manner, using 7-nitroindazole as starting material.

EXAMPLE 86 1-(Dimethylaminoethyl)-7-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 87 1-(1-Methylpiperid-4-yl)-7-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 88 1-[3-(4-Benzylpiperid-1-yl)propyl]-7-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 89 1-{3-[4-(2-Phenylethyl)piperazin-1-yl]propyl}-7-([1,2,4]triazol-4-yl)indazole dihydrochloride EXAMPLE 90 1-{3-[4-(5-Methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-7-([1,2,4]triazol-4-yl)indazole dihydrochloride PHARMACOLOGICAL STUDY OF THE COMPOUNDS OF THE INVENTION Example A

Contraction of the Saphenous Vein

The test are carried out on saphenous veins of dogs (10-25 kg) or of rabbits (2-3 kg) which have ben anaesthetised with pentobarbital (30 mg/kg i.v.). The saphenous veins are removed quickly and cut into rings. The rings are mounted between two hooks in vessels maintained at 37° C. containing physiological saline (composition in mM:NaCl 118.3; KCl 4.7; CaCl₂ 2.5; MgSO₄ 1.2; KH₂ PO₄ 1.2; NaHCO₃ 25.0; Ca-EDTA 0.026 and glucose 11.1).

A mixture of 95% O₂ --5% CO₂ is bubbled through the physiological saline solution. The lower hook consists of the fixed point whilst the upper hook is connected to an isometric force sensor. The tissues are subjected to a base tension of 1.5 grammes (dog) and of 1 gramme (rabbit). The test pharmacological substances are prepared immediately prior to use; they are solubilised in water or in dimethyl sulphoxide.

After being mount, the preparations are left to rest for 60 minutes, rinsing operations being carried out every 30 minutes. The organ is then placed in the presence of phenoxybenzamine (5×10^-8 M) for 20 minutes. That agent is eliminated by a number of successive washing operations over the course of 45 minutes. After readjustment of the base tension, contraction is brought about by KCl (100 mM). After washing and return to the base line, contraction is induced by 5-hydroxytryptamine (10^-5 M).

After washing and return to the base line, a dose/response curve for the pharmacological substances is produced by the addition of cumulative doses (10^-9 to 10^-4 M).

The test enables the 50% effective concentration (EC₅₀) of the compounds of the invention to be determined.

The EC₅₀ is calculated in the following manner: the tension values are first converted into percentages relative to the maximum effect induced by KCl. The effective concentration 50% (ED₅₀) is determined by non-linear regression according to the model of the law of mass action of Michaelis-Menten.

Results

The compounds of Examples 5 and 6 contract the saphenous vein of rabbits at EC₅₀ values of 0.30 μM and 0.12 μM, respectively, and with maximum responses of 75% and 87%, respectively.

On the saphenous vein of dogs, the EC₅₀ of the compound of Example 6 is 0.17 μM and the maximum response is 47%. The compound of Example 5 brings about a maximum contraction of 6% at a concentration of 100 μM.

Example B

Pharmaceutical Compositions

Formulation for the preparation of 1000 tablets each comprising 10 mg of active ingredient:

Compound of Example 5 . . . 10 g

Hydroxypropyl cellulose . . . 2 g

Wheat starch . . . 10 g

Lactose . . . 100 g

Magnesium stearate . . . 3 g

Talc . . . 3 g

Claims

We claim:

1. A compound selected from those of formula (I): ##STR16## wherein: n is 0 or 1,

A represents a σ bond or linear or branched (C₁ -C₈)alkylene, or linear or branched (C₁ -C₈)alkenylene,

X represents nitrogen or C--R₂ wherein R₂ represents hydrogen, or linear or branched (C₁ -C₆)alkyl,

R₁ represents hydrogen, or linear or branched (C₁ -C₆)alkyl,

G₁ represents ##STR17## wherein: R₃ and R₄ each independently of the other represent hydrogen, linear or branched (C₁ -C₆)alkyl, (C₃ -C₇)cycloalkyl, (C₃ -C₇)cycloalkyl-(C₁ -C₆)-alkyl in which the alkyl is linear or branched, optionally substituted aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, or optionally substituted aryl, or together with the nitrogen atom that carries them, R₃ and R₄ form a group: ##STR18## wherein B represents a σ bond or linear or branched (C₁ -C₆)alkylene, and R₅ represents hydrogen, linear or branched (C₁ -C₆)alkyl, (C₃ -C₆)-cycloalkyl, optionally substituted aryl, optionally substituted aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, optionally substituted heteroaryl, or optionally substituted heteroaryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, it being understood that:

"aryl" is understood to mean a group selected from phenyl and naphthyl,

"heteroaryl" is understood to mean a group selected from furyl, thienyl, pyridyl, pyrrolyl, imidazolyl, tetrazolyl, pyrazinyl and pyrimidinyl,

and the term optionally substituted applied to the terms "phenyl", "benzyl", "aryl", "arylalkyl", "heteroaryl" and "heteroarylalkyl" means that the groups in question may be substituted by one or more halogen, linear or branched (C₁ -C₆)alkyl, linear or branched (C₁ -C₆)alkoxy, hydroxy, and/or linear or branched (C₁ -C₆)trihaloalkyl.

2. A compound of claim 1 wherein the triazolyl or triazolylmethyl is attached to the 6-position of the indole or indazole, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

3. A compound of claim 1 wherein the triazolyl or triazolylmethyl group is attached to the 5-position of the indole or indazole group, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

4. A compound of claim 1 wherein n=0, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

5. A compound of claim 1 wherein X represent C--R₂ wherein R₂ represents hydrogen or linear or branched (C₁ -C₆)alkyl, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

6. A compound of claim 2 wherein X represents nitrogen, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

7. A compound of claim 1 wherein A represents a σ bond or linear or branched (C₁ -C₆)alkylene, and G₁ represents ##STR19## wherein B represent a σ bond or linear or branched (C₁ -C₆)alkylene, and R₅ represents hydrogen, linear or branched (C₁ -C₆)alkyl, (C₃ -C₆)cycloalkyl, optionally substituted aryl, optionally substituted aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, optionally substituted heteroaryl, or optionally substituted heteroaryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

8. A compound of claim 1 wherein A represent linear or branched (C₁ -C₆)alkylene and G₁ represents ##STR20## wherein R₃ and R₄ each independently of the other represents hydrogen, linear or branched (C₁ -C₆)alkyl, (C₃ -C₇)cycloalkyl, (C₃ -C₇)cycloalkyl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, optionally substituted aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, or optionally substituted aryl, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

9. A compound of claim 1 wherein the triazolyl or triazolylmethyl is attached to the 6-position of the indole or indazole, X represent --CH-- or nitrogen, R₁ represent hydrogen, A represents a σ bond or linear or branched (C₁ -C₆)alkylene and G₁ represents 1-piperazinyl optionally substituted on the nitrogen in the 4-position by linear or branched (C₁ -C₆)alkyl, optionally substituted aryl, optionally substituted aryl-(C₁ -C₆)alkyl in which the alkyl is linear or branched, optionally substituted heteroaryl, or optionally substituted heteroaryl-(C₁ -C₆)-alkyl in which the alkyl is linear or branched, or alternatively A represents linear or branched (C₁ -C₆)alkylene and G₁ represents ##STR21## wherein R₃ and R₄ each independently of the other represent hydrogen or linear or branched (C₁ -C₆)alkyl, their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

10. A compound of claim 1 which is selected from 1-(dimethylaminoethyl)-6-([1,2,4]triazol-4-yl)indole, and an addition salt thereof with a pharmaceutically-acceptable acid.

11. A compound of claim 1 which is selected from 1-(dimethylaminoethyl)-6-([1,2,4]triazol-4-yl)indazole, and an addition salt thereof with a pharmaceutically-acceptable acid.

12. A compound of claim 1 which is selected from 1-{3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indole, and an addition salt thereof with a pharmaceutically-acceptable acid.

13. A compound of claim 1 which is selected from 1-{3-[4-(5-methoxypyrimidin-4-yl)piperazin-1-yl]propyl}-6-([1,2,4]triazol-4-yl)indazole, and an addition salt thereof with a pharmaceutically-acceptable salt.

14. A method for treating a living body afflicted with venous insufficiency, and/or migraine, and/or migraine associated with vascular diseases, comprising the step of administering to the living body an amount of a compound of claim 1 which is effective for alleviation of said conditions.

15. A pharmaceutical composition comprising as active principle an effective amount of a compound of claim 1 in combination with one or more pharmaceutically-acceptable excipients or vehicles.

16. A method for treating a living body afflicted with venous insufficiency, and/or migraine, and/or migraine associated with vascular diseases, comprising the step of administering to the living body an amount of a compound of claim 9 which is effective for alleviation of said condition.

17. A pharmaceutical composition comprising as active principle an effective amount of a compound of claim 9 in combination with one or more pharmaceutically-acceptable excipients or vehicles.